Back to News
Market Impact: 0.3
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookRegulation & Legislation
Compass Pathways said it remains on track to complete the rolling New Drug Application submission for COMP360 in Q4. The company is building commercial infrastructure for a potential U.S. launch, contingent on FDA approval and federal rescheduling, providing a constructive regulatory and commercialization outlook for CMPS.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
CMPS0.55
More News
- Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Banks, investors grow wary of AI debt, spooked by market selloff
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- UniCredit CEO Plots Commerzbank Governance Overhaul